Despite many scientific advancements, we haven’t found satisfactory treatment for many dermatomes. The disFig.ment caused by these conditions is a source of distress. Pathophysiology of certain dermatomes roots from common pathophysiology. Though lots of medical treatments are available, however, they provide transient relief. Symptoms often re-appear after sometime.The conditions have a negative effect on overall quality of life of the patients leading to anxiety and depression in some cases. Usually these conditions take a long time to be asymptomatic only to relapse later. Janus kinase inhibitors (Jaknibs) are novel medications approved to be used in rheumatological conditions. Increasing evidences have shown their efficacy in many dermatological conditions such as psoriasis, vitiligo, atopic dermatitis, alopecia areata and a few others. Tofacitinib was first approved in 2012 by USFDA for the management of rheumatoid arthritis. Tofacitinib inhibits JAK1 and JAK3, reducing the signaling of pro-inflammatory cytokines. This inhibition affects various immune processes, which is beneficial in treating inflammatory and autoimmune conditions, including those affecting the skin.The drug is being accepted in dermatological conditions. In many other dermatoses, JAK inhibitors carry a promise in management. Cutaneous graftversus-host disease, erythema multiforme, dermatomyositis, chronic actinic dermatitis, and lupus and hypereosinophilic syndrome are few of such conditions. In the present review, we discuss the literature and evidence of the use of tofacitinib in dermatological conditions.